Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
暂无分享,去创建一个
J. Tamburini | S. Maira | N. Ifrah | C. Lacombe | P. Mayeux | Aymeric Neyret | D. Bouscary | Sophie Park | C. Vignon | F. Dreyfus | O. Hérault | N. Chapuis | V. Bardet | A. Green | L. Willems | S. Chapuis | M. Pannetier | Alexandre Macone | Sophie Park | ric Neyret | ur-Michel Maira | rine Lacombe | François Dreyfus | Didier Bouscary
[1] D. Dittmer,et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. , 2010, Blood.
[2] J. Tamburini,et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody , 2010, Haematologica.
[3] Jing Chen,et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.
[4] Charles P. Lin,et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. , 2010, Blood.
[5] P. Lollini,et al. NVP-BEZ235 as a New Therapeutic Option for Sarcomas , 2010, Clinical Cancer Research.
[6] D. Fingar,et al. mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action* , 2009, The Journal of Biological Chemistry.
[7] J. Tamburini,et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.
[8] Kevin Curran,et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. , 2009, Cancer research.
[9] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[10] N. Munshi,et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. , 2009, Cancer research.
[11] C. Chresta,et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.
[12] D. Hedley,et al. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts , 2009, British Journal of Cancer.
[13] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[14] Gerard Manning,et al. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.
[15] D. Guertin,et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.
[16] Robbie Loewith,et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.
[17] D. Alessi,et al. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.
[18] T. Maeda,et al. Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin* , 2008, Journal of Biological Chemistry.
[19] E. Estey,et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years , 2008, Cancer.
[20] S. Fröhling,et al. Deregulation of signaling pathways in acute myeloid leukemia. , 2008, Seminars in oncology.
[21] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[22] K. Shokat,et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.
[23] J. Tamburini,et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.
[24] X. Bai,et al. Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38 , 2007, Science.
[25] F. Khuri,et al. Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation , 2007, Molecular and Cellular Biology.
[26] Philippe Broët,et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.
[27] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[28] D. Sabatini,et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.
[29] C. Billottet,et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.
[30] N. Sonenberg,et al. mTOR, translation initiation and cancer , 2006, Oncogene.
[31] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[32] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[33] Steven M Kornblau,et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.
[34] E. Solary,et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .
[35] G. Laurent,et al. Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.
[36] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[37] E. Solary,et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.
[38] R. Loewith,et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.
[39] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[40] M. Clemens,et al. Targets and mechanisms for the regulation of translation in malignant transformation , 2004, Oncogene.
[41] J. Avruch,et al. Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[42] J. Arthur,et al. In vivo role of the PIF‐binding docking site of PDK1 defined by knock‐in mutation , 2003, The EMBO journal.
[43] M. Carroll,et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.
[44] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[45] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[46] S K Burley,et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.
[47] A. Gingras,et al. Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.
[48] A. C. Maiyar,et al. Serum and glucocorticoid‐inducible kinase (SGK) is a target of the PI 3‐kinase‐stimulated signaling pathway , 1999, The EMBO journal.
[49] P. Cohen,et al. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. , 1999, The Biochemical journal.
[50] A. Gingras,et al. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.